Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
LA Godoy, J Chen, W Ma, J Lally, KA Toomey… - Biomarker …, 2023 - Springer
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved …
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models
Longitudinal models of biomarkers such as tumour size dynamics capture treatment efficacy
and predict treatment outcome (overall survival) of a variety of anticancer therapies …
and predict treatment outcome (overall survival) of a variety of anticancer therapies …
A new artificial intelligence approach using extreme learning machine as the potentially effective model to predict and analyze the diagnosis of anemia
The procedure to diagnose anemia is time-consuming and resource-intensive due to the
existence of a multitude of symptoms that can be felt physically or seen visually. Anemia also …
existence of a multitude of symptoms that can be felt physically or seen visually. Anemia also …
High neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio are associated with poor survival in patients with hemodialysis
J Zhang, X Lu, S Wang, H Li - BioMed Research International, 2021 - Wiley Online Library
Background. The neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio
(PLR) are markers for systemic inflammation condition. Although NLR has emerged as a risk …
(PLR) are markers for systemic inflammation condition. Although NLR has emerged as a risk …
[HTML][HTML] Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
L Mezquita, I Preeshagul, E Auclin, D Saravia… - European Journal of …, 2021 - Elsevier
Background dNLR at the baseline (B), defined by neutrophils/[leucocytes-neutrophils],
correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non–small-cell lung …
correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non–small-cell lung …
Modelling the association between biomarkers and clinical outcome: An introduction to nonlinear joint models
M Kerioui, J Bertrand, R Bruno… - British Journal of …, 2022 - Wiley Online Library
Nonlinear joint models are a powerful tool to precisely analyse the association between a
nonlinear biomarker and a time‐to‐event process, such as death. Here, we review the main …
nonlinear biomarker and a time‐to‐event process, such as death. Here, we review the main …
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients
Paclitaxel/platinum chemotherapy, the backbone of standard first‐line treatment of advanced
non‐small cell lung cancer (NSCLC), exhibits high interpatient variability in treatment …
non‐small cell lung cancer (NSCLC), exhibits high interpatient variability in treatment …
Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic …
T Chen, Y Zheng, L Roskos, DE Mager - Journal of Pharmacokinetics and …, 2023 - Springer
Standard endpoints such as objective response rate are usually poorly correlated with
overall survival (OS) for treatment with immune checkpoint inhibitors. Longitudinal tumor …
overall survival (OS) for treatment with immune checkpoint inhibitors. Longitudinal tumor …
Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC
Background Lack of biomarkers and in vitro models has contributed to inadequate
understanding of the mechanisms underlying the inferior clinical response to immune …
understanding of the mechanisms underlying the inferior clinical response to immune …
Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐and on‐Treatment Prognostic Biomarkers
S Benzekry, M Karlsen, C Bigarré… - Clinical …, 2024 - Wiley Online Library
Existing survival prediction models rely only on baseline or tumor kinetics data and lack
machine learning integration. We introduce a novel kinetics‐machine learning (kML) model …
machine learning integration. We introduce a novel kinetics‐machine learning (kML) model …